Royalty Pharma plc
Price Action
Technical Summary
STAGE 2 UPTRENDRoyalty Pharma plc is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings contraction of 45% provides fundamental context to the price action. However, with RSI at 82, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $45.29 | +4.72% | ABOVE |
| 50 SMA | $42.16 | +12.51% | ABOVE |
| 100 SMA | $40.19 | +18.01% | ABOVE |
| 150 SMA | $38.87 | +22.01% | ABOVE |
| 200 SMA | $37.88 | +25.22% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RPRX in an uptrend right now?
RPRX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RPRX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RPRX overbought or oversold?
RPRX's RSI (14) is 82. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RPRX outperforming the market?
RPRX has a Relative Strength (RS) Rating of 80 out of 99. Yes, RPRX is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is RPRX in its 52-week range?
RPRX is trading at $47.43, which is 99% of its 52-week high ($47.86) and 98% above its 52-week low ($29.66).
How volatile is RPRX?
RPRX has a Beta of 0.36 and 52-week volatility of 23%. It's less volatile than the S&P 500 - generally more stable.